Abstract |
Progress in clinical intrathecal chemotherapy has been slow, and a number of new problems have been encountered. The most significant recent developments include the: 1) success of adjunctive intrathecal chemotherapy in the prevention of meningeal leukemia; 2) recognition and characterization of a necrotizing leukoencephalopathic reaction associated with intrathecal methotrexate therapy; 3) demonstration of the efficacy of intraventricular chemotherapy via an Ommaya reservoir; 4) delineation of the clinical pharmacology of intralumbar and intraventricular methotrexate; and 5) identification of an urgent need for new drugs and techniques for intrathecal administration.
|
Authors | W A Bleyer |
Journal | National Cancer Institute monograph
(Natl Cancer Inst Monogr)
Vol. 46
Pg. 171-8
(Dec 1977)
ISSN: 0083-1921 [Print] United States |
PMID | 580638
(Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
- Antineoplastic Agents
- Methotrexate
|
Topics |
- Animals
- Antineoplastic Agents
(administration & dosage)
- Arachnoiditis
(chemically induced)
- Child
- Humans
- Injections, Intraventricular
(methods)
- Injections, Spinal
- Leukemia
(drug therapy)
- Leukoencephalopathy, Progressive Multifocal
(chemically induced)
- Meningeal Neoplasms
(cerebrospinal fluid, drug therapy)
- Methotrexate
(administration & dosage, adverse effects, cerebrospinal fluid)
- Research Design
|